Longer-term use of pioglitazone associated with an increased risk of bladder cancer Full Text
Drug Topics, 08/10/2011
Clinical Article
FDA published an online safety communication informing prescribers and patients that pioglitazone (Actos, Takeda Pharmaceuticals America Inc) use may be associated with a 20% to 40% increased hazard of new bladder cancer.






